Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments
Hepatology · 2023-05 · 77 (5) · 1566-1579
DOI: 10.1002/hep.32707 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology, online erschienen am 17.04.2023. Verfasst von Daniel J Zabransky und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center , the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background and Aims: The treatment of hepatocellular carcinoma (HCC) has been transformed by the use of immune checkpoint inhibitors. However, most patients with HCC do not benefit from treatment with immunotherapy. There is an urgent need to understand the mechanisms that underlie response or resistance to immunotherapy for patients with HCC. The use of syngeneic mouse models that closely recapitulate the heterogeneity of human HCC will provide opportunities to examine the complex interactions between cancer cells and nonmalignant cells in the tumor microenvironment. Approach and Results: We leverage a multifaceted approach that includes imaging mass cytometry and suspension cytometry by time of flight to profile the tumor microenvironments of the Hep53.4, Hepa 1‐6, RIL‐175, and TIBx (derivative of TIB‐75) syngeneic mouse HCC models. The immune tumor microenvironments vary across these four models, and various immunosuppressive pathways exist at baseline in orthotopic liver tumors derived from these models. For instance, TIBx, which is resistant to anti–programmed cell death protein 1 therapy, contains a high proportion of “M2‐like” tumor‐associated macrophages with the potential to diminish antitumor immunity. Investigation of The Cancer Genome Atlas reveals that the baseline immunologic profiles of Hep53.4, RIL‐175, and TIBx are broadly representative of human HCCs; however, Hepa 1‐6 does not recapitulate the immune tumor microenvironment of the vast majority of human HCCs. Conclusions: There is a wide diversity in the immune tumor microenvironments in preclinical models and in human HCC, highlighting the need to use multiple syngeneic HCC models to improve the understanding of how to treat HCC through immune modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center , the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine , Baltimore , Maryland , USA.
- Flow/Mass Cytometry Facility, Sidney Kimmel Comprehensive Cancer Center , Johns Hopkins University School of Medicine , Baltimore , Maryland , USA.
- The Cancer Convergence Institute at the Johns Hopkins University School of Medicine , Baltimore , Maryland , USA.
ORCID-Profile: Daniel J Zabransky
Förderung
- NCI NIH HHS
Zitieren
APA
Zabransky, D. J., Danilova, L., Leatherman, J. M., Lopez-Vidal, T. Y., Sanchez, J., Charmsaz, S., Gross, N. E., Shin, S., Yuan, X., Hernandez, A., Yang, H., Xavier, S., Shu, D., Saeed, A., Munjal, K., Kamdar, Z., Kagohara, L. T., Jaffee, E. M., Yarchoan, M., & Ho, W. J. (2023). Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments. Hepatology, 77(5), 1566-1579. https://doi.org/10.1002/hep.32707
Vancouver
Zabransky DJ, Danilova L, Leatherman JM, Lopez-Vidal TY, Sanchez J, Charmsaz S, et al. Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments. Hepatology. 2023;77(5):1566-1579. doi:10.1002/hep.32707
BibTeX
@article{Zabransky2023,
author = {Zabransky, Daniel J and Danilova, Ludmila and Leatherman, James M and Lopez-Vidal, Tamara Y and Sanchez, Jessica and Charmsaz, Soren and Gross, Nicole E and Shin, Sarah and Yuan, Xuan and Hernandez, Alexei and Yang, Hongqui and Xavier, Stephanie and Shu, Daniel and Saeed, Ali and Munjal, Kabeer and Kamdar, Zeal and Kagohara, Luciane T and Jaffee, Elizabeth M and Yarchoan, Mark and Ho, Won Jin},
title = {Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments},
journal = {Hepatology},
year = {2023},
volume = {77},
number = {5},
pages = {1566--1579},
doi = {10.1002/hep.32707}
}
EUVIMED